<DOC>
	<DOCNO>NCT02609139</DOCNO>
	<brief_summary>This Phase 1 , open-label , single-dose , within-cohort randomize , 2-way crossover study evaluate PK orally administer PF-06650833 modify release tablet fast high fat meal feed condition healthy subject .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics A Modified Release Formulation PF-06650833 Healthy Subjects</brief_title>
	<detailed_description>This third study PF-06650833 . The goal study assess PK healthy subject single dos modify release ( MR ) tablets PF-06650833 orally administer fasting high fat meal feed condition .</detailed_description>
	<criteria>1 . Healthy female subject non childbearing potential and/or male subject , age 18 55 year 2 . BMI 17.5 30.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . 3 . Personally sign date Informed Consent 4 . Willing able comply schedule visit , treatment plan , laboratory test , study procedure . 1 . Clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease 2 . Any condition possibly affect drug absorption 3 . Positive urine drug screen . 4 . Heavy smoker 5 . History regular heavy alcohol consumption within 6 month Screening . 6 . Treatment investigational drug within 30 day ( determined local requirement ) 5 half live 7 . Screening supine blood pressure &lt; =100 mm Hg ( systolic ) &lt; =50 mm Hg ( diastolic ) &gt; =140 mm Hg ( systolic ) &gt; =90 mm Hg ( diastolic ) , follow least 5 minute supine rest . 8 . Screening pulse ( HR ) &gt; 100 bpm least 5 minute rest . 9 . Single supine 12 lead ECG demonstrate QTc &gt; 450 msec QRS interval &gt; 120 msec Screening . 10 . Abnormal chest X ray 11 . History TB active latent inadequately treated infection , positive Quantiferon TB test . 12 . History hepatitis positive test human HIV , HepBsAg , HepBc Ab HCVAb 13 . Any medical history disease [ ie , Gilbert 's disease ] potential cause rise total bilirubin ULN 14 . Clinical laboratory abnormality include : Creatine kinase &gt; 1.2 X ULN ; CK MB &gt; ULN ; Serum myoglobin &gt; 1.2 X ULN ; Cardiac Troponin I ( cTn I ) &gt; ULN laboratory reference range ; Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) &gt; =2 x ULN , total serum bilirubin &gt; =1.5 mg/dL ; Subjects benign ethnic neutropenia ; Hemoglobin &lt; =14 gm/dl ( male ) &lt; =13 gm/dL ( female ) . 15 . Nursing female subject ; male subject partner currently pregnant ; male subject able father child unwilling unable use highly effective method contraception outline protocol duration study 28 day last dose investigational product longer base upon compound 's half life characteristic . 16 . Use prescription nonprescription drug dietary supplement within 7 day 5 half life ( whichever longer ) prior first dose investigational product discharge study end Period 2 . Herbal supplement hormone replacement therapy must discontinue 28 day prior first dose investigational product . Acetaminophen/paracetamol use . As exception , ibuprofen may use dos 200 400 mg orally every 6 hour need 3 7 consecutive day . 17 . Blood donation ( exclude plasma donation ) approximately 1 pint ( 500 mL ) within 56 day prior dose . 18 . History sensitivity heparin heparin induce thrombocytopenia . 19 . History cancer ( treat basal cell squamous cell carcinoma skin ) previous 5 year . 20 . Previous exposure PF 06650833 . 21 . Unwilling unable comply Lifestyle guideline 22 . Subjects investigational site staff member directly involved conduct study family member , site staff member otherwise supervised Investigator , subject Pfizer employee directly involve conduct study . 23 . Other severe acute chronic medical psychiatric condition laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>